Axl-IN-3

Cat. No.:	HY-144706
CAS No.:	2783991-34-2
Molecular Formula:	$C_{24}H_{25}ClN_6O_2$
Molecular Weight:	464.95
Target:	TAM Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC_{50} of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases[1].
IC_{50} & Target	IC50: 41.5 nM (AXL kinase)[1]
In Vitro	Axl-IN-3 (Compound 54) shows anti-proliferative activity in SKOV3 cells with a GI_{50} of 1.02 μM[1]. Axl-IN-3 (Compound 54; 1-10 μM; pretreated 1 h) inhibits AXL signaling in SKOV3 cells. Axl-IN-3 shows a dose dependent reduction of phosphorylated AXL (pAXL) levels compared to untreated cells. Additionally, the reduction of pAXL levels also lead to the concomitant reduction in downstream pERK1/2 levels[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Pharmacokinetic studies of Axl-IN-3 (Compound 54) at 5 mg/kg reveal rapid oral absorption with a T_{max} of 0.25 hr, C_{max} of 460 ng/mL, $T_{1/2}$ of 2.46 hr, and area under the curve (AUC) values of 1620 (ng*hr/mL)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pearly Shuyi Ng, et al. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors. Bioorg Med Chem. 2021 Nov 1;49:116437.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA